Vaccines

The production of animal vaccines requires highly secure and controlled manufacturing process environments in which adventitious contaminations such as viruses and bacteria are strictly forbidden from end-products for safety reasons.

The biopharma companies and Contract Manufacturing Organizations (CMO) are actively looking for new, more robust, more sensitive and faster diagnostic PCR-based tests to comply with tighter and tighter safety regulations and to mitigate contaminations originating from bacteria, molds, yeasts, viruses, Mycoplasma, as well as cross contamination by other cell lines.

Progenus proposes PCR and Next Generation Sequencing (NGS) -based services:

• Design and validation of in-vitro diagnostics and analysis tests.
• Identification of viral and bacterial contaminants.
• Detection of the presence of host-cell genomic DNA, gDNA, in biopharma processes.